- Medical School - Harvard Medical School (1999-2004)
- Internship - Columbia University/St. Luke's - Roosevelt Hospital Center (2004-2005), Internal Medicine
- Residency - Harvard/Brigham and Women's Hospital/Massachusetts General Hospital (2005-2009)
Andrew Wang, M.D.
Associate Vice Chair for Research
- A. Kenneth Pye Professorship in Cancer Research
- Radiation Oncology
- Genitourinary Cancer
- Gastrointestinal Cancers
Andrew Z. Wang, M.D., grew up with two parents who were both mathematicians. He planned to attend graduate school for mathematics, but shortly after he started college he found that wasn’t his path. It was during his junior year of college that he decided his passion was in medical research.
“I actually thought I’d be a Ph.D. and spend my time in research,” he says. “My interest in becoming a physician started with my interest in medical science and that led me to go to medical school.”
Dr. Wang obtained his medical degree from the Harvard-MIT Health Sciences and Technology (HST) program at Harvard Medical School. He also earned two bachelor of science degrees in biochemistry and biology and a bachelor of arts degree from Indiana University with highest distinction. After an internship in internal medicine at St. Luke’s Roosevelt Hospital in New York, he completed clinical training in radiation oncology in the Harvard Radiation Oncology Program. Following residency, Dr. Wang joined the faculty at University of North Carolina as Assistant Professor in the Department of Radiation Oncology.
Dr. Wang is currently Professor of Radiation Oncology and Associate Vice Chair for Research at UT Southwestern Medical Center. He holds the A. Kenneth Pye Professorship in Cancer Research.
“Radiation oncology is a unique blend of medicine, science, and technology and is a field where advances from research can quickly translate into practice in clinical medicine,” says Dr. Wang. “The ability to rapidly impact patient care through research is one of the reasons that inspired me to pursue a career as a physician-scientist in radiation oncology.”
Dr. Wang specializes in the treatment of genitourinary and gastrointestinal cancers and is familiar with different radiation techniques, including IMRT, IGRT, linac-based SRS, SBRT, and intraoperative radiotherapy and interstitial brachytherapy. In the clinic, he strives to treat his patients as if they are his own family.
“I want to carefully listen to patients and be their ally,” he says. “I’d like them to know that I will give all of myself to them and will do my best to make sure they receive the highest level of care. That’s how I think about and approach patient care.”
- American Society of Clinical Oncology (ASCO) (2009)
- American Society for Radiation Oncology (ASTRO) (2006)
- American Association for Cancer Research (AACR) (2007)
- Journal of the National Cancer Institute (2017), Member, Editorial Board
- BMC Cancer (2018), Associate Editor
- Nanomedicine: Nanotechnology, Biology, and Medicine (2015), Associate Editor
- Elected Member of the American Society for Clinical Investigation (ASCI)
- “America’s Top Doctors” by Castle Connolly 2020
- UNC Health Care and Faculty Physicians Award for Carolina Care Excellence
- American Institute for Medical and Biological Engineering (AIMBE) College of Fellows
- ASCO Leadership Development Program
- Science Translational Medicine, Associate Scientific Advisor
- ASTRO Biology Basic Science Research Abstract Award
- ASTRO Junior Faculty Basic Science Research Abstract Award
- ASTRO Translational Research Meeting Travel Grant
- ASTRO Resident Poster Recognition Biology Award (Biology)
- Howard Hughes Medical Institute Research Fellowship for Medical Students
- Harvard Medical School, Betty and Doris Barrett Scholarship
Nanotechnology and aptamers: applications in drug delivery.
Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC, Trends in biotechnology 2008 Aug 26 8 442-9
Biofunctionalized targeted nanoparticles for therapeutic applications.
Wang AZ, Gu F, Zhang L, Chan JM, Radovic-Moreno A, Shaikh MR, Farokhzad OC, Expert opinion on biological therapy 2008 Aug 8 8 1063-70
HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.
Alexis F, Basto P, Levy-Nissenbaum E, Radovic-Moreno AF, Zhang L, Pridgen E, Wang AZ, Marein SL, Westerhof K, Molnar LK, Farokhzad OC, ChemMedChem 2008 Dec 3 12 1839-43
Nanoparticles in medicine: therapeutic applications and developments.
Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC, Clinical pharmacology and therapeutics 2008 May 83 5 761-9
ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.
Wang AZ, Yuet K, Zhang L, Gu FX, Huynh-Le M, Radovic-Moreno AF, Kantoff PW, Bander NH, Langer R, Farokhzad OC, Nanomedicine (London, England) 2010 Apr 5 3 361-8
Chemoradiation therapy in the management of gastrointestinal malignancies.
McRee AJ, Cowherd S, Wang AZ, Goldberg RM, Future oncology (London, England) 2011 Mar 7 3 409-26
Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.
Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ, Biomaterials 2011 Nov 32 33 8548-54
Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy.
Werner ME, Copp JA, Karve S, Cummings ND, Sukumar R, Li C, Napier ME, Chen RC, Cox AD, Wang AZ, ACS nano 2011 Nov 5 11 8990-8
Formulation of diblock polymeric nanoparticles through nanoprecipitation technique.
Karve S, Werner ME, Cummings ND, Sukumar R, Wang EC, Zhang YA, Wang AZ, Journal of visualized experiments : JoVE 2011 Sep 55
Chemoradiotherapy of human tumors: novel approaches from nanomedicine.
Werner ME, Foote MB, Wang AZ, Current pharmaceutical design 2012 18 19 2830-7
Nanoparticle delivery of cancer drugs.
Wang AZ, Langer R, Farokhzad OC, Annual review of medicine 2012 63 185-98
Preparation of neutron-activatable holmium nanoparticles for the treatment of ovarian cancer metastases.
Di Pasqua AJ, Huckle JE, Kim JK, Chung Y, Wang AZ, Jay M, Lu X, Small (Weinheim an der Bergstrasse, Germany) 2012 Apr 8 7 997-1000
Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE, BJU international 2012 Dec 110 11 Pt B E721-6
Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery.
Karve S, Werner ME, Sukumar R, Cummings ND, Copp JA, Wang EC, Li C, Sethi M, Chen RC, Pacold ME, Wang AZ, Proceedings of the National Academy of Sciences of the United States of America 2012 May 109 21 8230-5
Nanoparticle drug delivery: focusing on the therapeutic cargo.
Wang AZ, Nanomedicine (London, England) 2012 Oct 7 10 1463-5
Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A surveillance, epidemiology and end results patterns of care study.
Holmes JA, Wang AZ, Hoffman KE, Hendrix LH, Rosenman JG, Carpenter WR, Godley PA, Chen RC, International journal of radiation oncology, biology, physics 2012 Sep 84 1 88-94
Application of liposomal technologies for delivery of platinum analogs in oncology.
Liu D, He C, Wang AZ, Lin W, International journal of nanomedicine 2013 8 3309-19
Improving chemoradiotherapy with nanoparticle therapeutics.
Eblan MJ, Wang AZ, Translational cancer research 2013 Aug 2 4 320-329
Nanomedicine in chemoradiation.
Miller SM, Wang AZ, Therapeutic delivery 2013 Feb 4 2 239-50
Biotargeted nanomedicines for cancer: six tenets before you begin.
Goldberg MS, Hook SS, Wang AZ, Bulte JW, Patri AK, Uckun FM, Cryns VL, Hanes J, Akin D, Hall JB, Gharkholo N, Mumper RJ, Nanomedicine (London, England) 2013 Feb 8 2 299-308
Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer.
Werner ME, Cummings ND, Sethi M, Wang EC, Sukumar R, Moore DT, Wang AZ, International journal of radiation oncology, biology, physics 2013 Jul 86 3 463-468
Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study.
Stokes WA, Hendrix LH, Royce TJ, Allen IM, Godley PA, Wang AZ, Chen RC, Cancer 2013 Jul 119 13 2486-93
Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy.
Chu KS, Schorzman AN, Finniss MC, Bowerman CJ, Peng L, Luft JC, Madden AJ, Wang AZ, Zamboni WC, DeSimone JM, Biomaterials 2013 Nov 34 33 8424-9
Nanoparticle Formulations of siRNA: The Next Generation of Targeted Therapy for Lymphomas and Leukemias?
Wang AZ, EBioMedicine 2014 Dec 1 2-3 101-2
Differential cell responses to nanoparticle docetaxel and small molecule docetaxel at a sub-therapeutic dose range.
Wang EC, Sinnott R, Werner ME, Sethi M, Whitehurst AW, Wang AZ, Nanomedicine : nanotechnology, biology, and medicine 2014 Feb 10 2 321-8
Receipt of guideline-concordant treatment in elderly prostate cancer patients.
Chen RC, Carpenter WR, Hendrix LH, Bainbridge J, Wang AZ, Nielsen ME, Godley PA, International journal of radiation oncology, biology, physics 2014 Feb 88 2 332-8
Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity.
Sethi M, Sukumar R, Karve S, Werner ME, Wang EC, Moore DT, Kowalczyk SR, Zhang L, Wang AZ, Nanoscale 2014 Feb 6 4 2321-2327
Nanotechnology in radiation oncology.
Wang AZ, Tepper JE, Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Sep 32 26 2879-85
A Randomized Pilot Trial Comparing Position Emission Tomography (PET)-Guided Dose Escalation Radiotherapy to Conventional Radiotherapy in Chemoradiotherapy Treatment of Locally Advanced Nasopharyngeal Carcinoma.
Wang J, Zheng J, Tang T, Zhu F, Yao Y, Xu J, Wang AZ, Zhang L, PloS one 2015 10 4 e0124018
Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery.
Tian X, Lara H, Wagner KT, Saripalli S, Hyder SN, Foote M, Sethi M, Wang E, Caster JM, Zhang L, Wang AZ, Nanoscale 2015 Dec 7 47 20211-9
Direct Observation of Early-Stage High-Dose Radiotherapy-Induced Vascular Injury via Basement Membrane-Targeting Nanoparticles.
Au KM, Hyder SN, Wagner K, Shi C, Kim YS, Caster JM, Tian X, Min Y, Wang AZ, Small (Weinheim an der Bergstrasse, Germany) 2015 Dec 11 48 6404-10
Local iontophoretic administration of cytotoxic therapies to solid tumors.
Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM, Science translational medicine 2015 Feb 7 273 273ra14
Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity.
Caster JM, Sethi M, Kowalczyk S, Wang E, Tian X, Nabeel Hyder S, Wagner KT, Zhang YA, Kapadia C, Man Au K, Wang AZ, Nanoscale 2015 Feb 7 6 2805-11
Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy.
Rocca JD, Werner ME, Kramer SA, Huxford-Phillips RC, Sukumar R, Cummings ND, Vivero-Escoto JL, Wang AZ, Lin W, Nanomedicine : nanotechnology, biology, and medicine 2015 Jan 11 1 31-8
Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors.
Wang EC, Min Y, Palm RC, Fiordalisi JJ, Wagner KT, Hyder N, Cox AD, Caster JM, Tian X, Wang AZ, Biomaterials 2015 May 51 208-215
Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles.
Au KM, Min Y, Tian X, Zhang L, Perello V, Caster JM, Wang AZ, ACS nano 2015 Sep 9 9 8976-96
Accurate Segmentation of CT Male Pelvic Organs via Regression-Based Deformable Models and Multi-Task Random Forests.
Gao Y, Shao Y, Lian J, Wang AZ, Chen RC, Shen D, IEEE transactions on medical imaging 2016 06 35 6 1532-43
Nanoparticle formulation of small DNA molecules, Dbait, improves the sensitivity of hormone-independent prostate cancer to radiotherapy.
Yao H, Qiu H, Shao Z, Wang G, Wang J, Yao Y, Xin Y, Zhou M, Wang AZ, Zhang L, Nanomedicine : nanotechnology, biology, and medicine 2016 11 12 8 2261-2271
Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.
Tian X, Warner SB, Wagner KT, Caster JM, Zhang T, Ohana P, Gabizon AA, Wang AZ, International journal of radiation oncology, biology, physics 2016 11 96 3 547-55
Prostate deformation from inflatable rectal probe cover and dosimetric effects in prostate seed implant brachytherapy.
Lian J, Shao Y, Potter LD, Chen RC, Holmes JA, Pryser EA, Shen J, Shen D, Wang AZ, Medical physics 2016 Dec 43 12 6569
Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM, Satterlee A, Min Y, Tian X, Kim YS, Caster JM, Zhang L, Zhang T, Huang L, Wang AZ, Biomaterials 2016 Mar 82 178-93
Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.
Shao Z, Wang AZ, George DJ, Zhang T, Asian journal of urology 2016 Oct 3 4 268-277
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.
Rose TL, Deal AM, Ladoire S, Créhange G, Galsky MD, Rosenberg JE, Bellmunt J, Wimalasingham A, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK, Chen RC, Wang AZ, Nielsen ME, Smith AB, Milowsky MI, Bladder cancer (Amsterdam, Netherlands) 2016 Oct 2 4 405-413
CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1a.
Tian X, Nguyen M, Foote HP, Caster JM, Roche KC, Peters CG, Wu P, Jayaraman L, Garmey EG, Tepper JE, Eliasof S, Wang AZ, Cancer research 2017 01 77 1 112-122
Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer.
Tian J, Min Y, Rodgers Z, Wan X, Qiu H, Mi Y, Tian X, Wagner KT, Caster JM, Qi Y, Roche K, Zhang T, Cheng J, Wang AZ, Nanomedicine : nanotechnology, biology, and medicine 2017 04 13 3 1301-1307
Effect of particle size on the biodistribution, toxicity, and efficacy of drug-loaded polymeric nanoparticles in chemoradiotherapy.
Caster JM, Yu SK, Patel AN, Newman NJ, Lee ZJ, Warner SB, Wagner KT, Roche KC, Tian X, Min Y, Wang AZ, Nanomedicine : nanotechnology, biology, and medicine 2017 07 13 5 1673-1683
Applying nanotherapeutics to improve chemoradiotherapy treatment for cancer.
Caster JM, Wang AZ, Therapeutic delivery 2017 08 8 9 791-803
Nanomedicine approaches to improve cancer immunotherapy.
Qiu H, Min Y, Rodgers Z, Zhang L, Wang AZ, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2017 09 9 5
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.
Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, DeSimone JM, Tepper JE, Vincent BG, Serody JS, Wang AZ, Nature nanotechnology 2017 09 12 9 877-882
Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models.
Tian J, Min Y, Rodgers Z, Au KM, Hagan CT, Zhang M, Roche K, Yang F, Wagner K, Wang AZ, Journal of materials chemistry. B 2017 Aug 5 30 6049-6057
Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages.
Lee MS, Dees EC, Wang AZ, Oncology (Williston Park, N.Y.) 2017 Mar 31 3 198-208
Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer.
Diao K, Lobos EA, Yirmibesoglu E, Basak R, Hendrix LH, Barbosa B, Miller SM, Pearlstein KA, Goldin GH, Wang AZ, Chen RC, Practical radiation oncology 2017 Mar - Apr 7 2 e117-e124
Bio-nano interface: The impact of biological environment on nanomaterials and their delivery properties.
Cai K, Wang AZ, Yin L, Cheng J, Journal of controlled release : official journal of the Controlled Release Society 2017 Oct 263 211-222
Nanotechnology Approaches to Improving Cancer Immunotherapy.
Hagan CT, Medik YB, Wang AZ, Advances in cancer research 2018 139 35-56
Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.
Hartshorn CM, Bradbury MS, Lanza GM, Nel AE, Rao J, Wang AZ, Wiesner UB, Yang L, Grodzinski P, ACS nano 2018 01 12 1 24-43
Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma.
Au KM, Tripathy A, Lin CP, Wagner K, Hong S, Wang AZ, Park SI, ACS nano 2018 02 12 2 1544-1563
Integration of biomimicry and nanotechnology for significantly improved detection of circulating tumor cells (CTCs).
Myung JH, Park SJ, Wang AZ, Hong S, Advanced drug delivery reviews 2018 02 125 36-47
Nanotechnology enabling the use of circulating tumor cells (CTCs) as reliable cancer biomarkers.
Hong S, Wang AZ, Advanced drug delivery reviews 2018 02 125 1-2
Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer.
Wan X, Min Y, Bludau H, Keith A, Sheiko SS, Jordan R, Wang AZ, Sokolsky-Papkov M, Kabanov AV, ACS nano 2018 03 12 3 2426-2439
Controlling release from 3D printed medical devices using CLIP and drug-loaded liquid resins.
Bloomquist CJ, Mecham MB, Paradzinsky MD, Janusziewicz R, Warner SB, Luft JC, Mecham SJ, Wang AZ, DeSimone JM, Journal of controlled release : official journal of the Controlled Release Society 2018 05 278 9-23
Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds.
Tian X, Werner ME, Roche KC, Hanson AD, Foote HP, Yu SK, Warner SB, Copp JA, Lara H, Wauthier EL, Caster JM, Herring LE, Zhang L, Tepper JE, Hsu DS, Zhang T, Reid LM, Wang AZ, Nature biomedical engineering 2018 06 2 6 443-452
Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.
Myung JH, Eblan MJ, Caster JM, Park SJ, Poellmann MJ, Wang K, Tam KA, Miller SM, Shen C, Chen RC, Zhang T, Tepper JE, Chera BS, Wang AZ, Hong S, Clinical cancer research : an official journal of the American Association for Cancer Research 2018 06 24 11 2539-2547
Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models.
Zhang M, Hagan CT, Min Y, Foley H, Tian X, Yang F, Mi Y, Au KM, Medik Y, Roche K, Wagner K, Rodgers Z, Wang AZ, Biomaterials 2018 07 169 1-10
Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy.
Mavroidis P, Pearlstein KA, Dooley J, Sun J, Saripalli S, Das SK, Wang AZ, Chen RC, Radiation oncology (London, England) 2018 Feb 13 1 17
A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy.
Mi Y, Smith CC, Yang F, Qi Y, Roche KC, Serody JS, Vincent BG, Wang AZ, Advanced materials (Deerfield Beach, Fla.) 2018 Jun 30 25 e1706098
A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy.
Moon DH, Wang AZ, Tepper JE, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2018 Mar 126 3 527-533
Cardiovascular Preventive Care and Coordination of Care in Prostate Cancer Survivors: A Multi-Institutional Prospective Study.
Holmes JA, Anderson RF, Hoffman LG, Showalter TN, Kasibhatla M, Collins SP, Papagikos MA, Barbosa BD, Alligood K, Stravers LJ, Mahbooba Z, Wang AZ, Chen RC, International journal of radiation oncology, biology, physics 2019 01 103 1 112-115
Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy.
Caster JM, Callaghan C, Seyedin SN, Henderson K, Sun B, Wang AZ, Advanced drug delivery reviews 2019 04 144 3-15
Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.
Sanoff HK, Moon DH, Moore DT, Boles J, Bui C, Blackstock W, O'Neil BH, Subramaniam S, McRee AJ, Carlson C, Lee MS, Tepper JE, Wang AZ, Nanomedicine : nanotechnology, biology, and medicine 2019 06 18 189-195
Nanotechnology in Radiation Oncology.
Sun B, Hagan CT, Caster J, Wang AZ, Hematology/oncology clinics of North America 2019 12 33 6 1071-1093
High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles.
Au KM, Balhorn R, Balhorn MC, Park SI, Wang AZ, ACS central science 2019 Jan 5 1 122-144
Emerging Nano-/Microapproaches for Cancer Immunotherapy.
Mi Y, Hagan CT, Vincent BG, Wang AZ, Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2019 Mar 6 6 1801847
Biologically Targeted Photo-Crosslinkable Nanopatch to Prevent Postsurgical Peritoneal Adhesion.
Mi Y, Yang F, Bloomquist C, Xia Y, Sun B, Qi Y, Wagner K, Montgomery SA, Zhang T, Wang AZ, Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2019 Oct 6 19 1900809
Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo.
Yang F, Medik Y, Li L, Tian X, Fu D, Brouwer KLR, Wagner K, Sun B, Sendi H, Mi Y, Wang AZ, Small (Weinheim an der Bergstrasse, Germany) 2020 02 16 7 e1906360
Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma.
Au KM, Wang AZ, Park SI, Science advances 2020 04 6 14 eaaz9798
Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine.
Hagan CT, Mi Y, Knape NM, Wang AZ, Bioconjugate chemistry 2020 12 31 12 2668-2678
Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma.
Walburn T, Grover NS, Shen CJ, Ranganathan R, Dittus C, Beaven AW, Wang AZ, Wang K, Leukemia & lymphoma 2021 01 62 1 68-75
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.
Hwang JK, Zhang T, Wang AZ, Li Z, Journal of hematology & oncology 2021 02 14 1 38
Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models.
Zhang M, Hagan CT, Foley H, Tian X, Yang F, Au KM, Mi Y, Medik Y, Roche K, Wagner K, Rodgers Z, Min Y, Wang AZ, Acta biomaterialia 2021 04 124 327-335
Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.
Brady-Nicholls R, Zhang J, Zhang T, Wang AZ, Butler R, Gatenby RA, Enderling H, Neoplasia (New York, N.Y.) 2021 Jul 23 9 851-858
Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies.
Sud S, Weiner AA, Wang AZ, Gupta GP, Shen CJ, Seminars in radiation oncology 2021 Oct 31 4 309-323
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.
Wang AZ, Bagalkot V, Vasilliou CC, Gu F, Alexis F, Zhang L, Shaikh M, Yuet K, Cima MJ, Langer R, Kantoff PW, Bander NH, Jon S, Farokhzad OC, ChemMedChem 2008 Sep 3 9 1311-5
Current progress of aptamer-based molecular imaging.
Wang AZ, Farokhzad OC, Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2014 Mar 55 3 353-6
Scoring the recurrence score in rectal cancer.
Tepper JE, Wang AZ, Journal of the National Cancer Institute 2014 Nov 106 11
Clinical Translation of Nanomedicine.
Min Y, Caster JM, Eblan MJ, Wang AZ, Chemical reviews 2015 Oct 115 19 11147-90
Application of nanotechnology to cancer radiotherapy.
Mi Y, Shao Z, Vang J, Kaidar-Person O, Wang AZ, Cancer nanotechnology 2016 7 1 11
Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.
Wang C, Sun W, Wright G, Wang AZ, Gu Z, Advanced materials (Deerfield Beach, Fla.) 2016 Oct 28 40 8912-8920
Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.
Wang C, Sun W, Wright G, Wang AZ, Gu Z, Advanced materials (Deerfield Beach, Fla.) 2017 04 29 15
Clinical indications for, and the future of, circulating tumor cells.
Moon DH, Lindsay DP, Hong S, Wang AZ, Advanced drug delivery reviews 2018 02 125 143-150
Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.
Brady-Nicholls R, Nagy JD, Gerke TA, Zhang T, Wang AZ, Zhang J, Gatenby RA, Enderling H, Nature communications 2020 04 11 1 1750
Quality-of-life Benefits and Harms from Prostate Radiotherapy in Patients with Low-burden Metastatic Prostate Cancer.
Royce TJ, Wang AZ, Chen RC, European urology 2021 02 79 2 198-199
Immune Checkpoint-Bioengineered Beta Cell Vaccine Reverses Early-Onset Type 1 Diabetes.
Au KM, Medik Y, Ke Q, Tisch R, Wang AZ, Advanced materials (Deerfield Beach, Fla.) 2021 Jun 33 25 e2101253
Improving local control in rectal cancer: radiation sensitizers or radiation dose?
Tepper JE, Wang AZ, Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Apr 28 10 1623-4
Nanoparticles and their applications in cell and molecular biology.
Wang EC, Wang AZ, Integrative biology : quantitative biosciences from nano to macro 2014 Jan 6 1 9-26
Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience.
Tahover E, Bar-Shalom R, Sapir E, Pfeffer R, Nemirovsky I, Turner Y, Gips M, Ohana P, Corn BW, Wang AZ, Gabizon AA, Frontiers in oncology 2018 8 544
Giving failed drugs a fresh chance: a new direction for nanoparticle drug delivery.
Wang AZ, Expert review of medical devices 2012 Sep 9 5 445-7
- Nanotechnology and aptamers: applications in drug delivery.
- Application of biomedical engineering to cancer research
- Developing novel cancer diagnostics and therapeutics to improve cancer treatment
- Genitourinary Cancer
- Gastrointestinal Cancers